---
title: "VK2735 in Chronic weight management: Pathophysiology"
description: "Formulary evidence on VK2735 in Chronic weight management: Pathophysiology. Topics: Energy homeostasis and the defended level of body fat; Central nervous system regulation of appetite and adipocyte mass; Gut-derived incretin hormones: GLP-1 and GIP; Adipose tissue expansion, inflammation, and ectopic fat; 4 further topics. 8 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/pathophysiology"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Energy homeostasis and the defended level of body fat

> “Growing evidence suggests that obesity is a disorder of the energy homeostasis system, rather than simply arising from the passive accumulation of excess weight.”
> “A major area of emphasis is the science of energy homeostasis, the biological process that maintains weight stability by actively matching energy intake to energy expenditure over time.”

Source: [Schwartz et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5546881/)

<a id="topic-2.2.1.4-2"></a>

### Central nervous system regulation of appetite and adipocyte mass

> “The subcortical brain regions interact with higher cortical brain areas and hormonal signals (eg, leptin and gut hormones such as GLP-1) to regulate adipocyte mass.”
> “Dysregulation in these neural circuits can lead to an imbalance between energy intake and expenditure, promoting uncontrolled fat accumulation, weight gain, and the development of obesity.”
> “NTS neurons express receptors for multiple satiety peptides such as leptin, melanocortin, and GLP-1, and are key contributors to satiety control.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.4-3"></a>

### Gut-derived incretin hormones: GLP-1 and GIP

> “GLP-1 is secreted by L-cell enteroendocrine cells in the small intestine and colon in response to intraluminal nutrients, in particular glucose and fat.”
> “GLP-1 further influences nutrient utilization, as do other incretin hormones, by promoting insulin secretion and inhibiting glucagon secretion.”
> “However, drug trials consistently demonstrate that GLP-1 receptor agonism results in significant weight loss.”
> “GIP, like GLP-1, is an incretin hormone though it has previously been shown to have a minimal effect on weight.”
> “However, combination GIP and GLP-1 agonism results in robust weight loss, potentially related to GIP’s unique alterations in adipose cell lipid cycling”

Source: [Busebee et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10843116/)

<a id="topic-2.2.1.4-4"></a>

### Adipose tissue expansion, inflammation, and ectopic fat

> “Hence, the pathophysiology of obesity not only involves an increase in total body fat, with preferential distribution to the intra-abdominal compartment in the presence of insulin resistance, but also ectopic lipid accrual into non-adipose tissues, especially in the liver, skeletal muscle, and the pancreas.”
> “Storing excess energy in adipocytes is associated with ischaemia and hypoxia, apoptosis, fibrosis, and a decrease in capillary density.”
> “Consequently, obesity functions as a chronically inflamed state that originates from adipose tissue but also occurs systemically.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.4-5"></a>

### Insulin resistance and cardiometabolic progression

> “However, a clear majority of people with obesity suffer varying degrees of insulin resistance.”
> “For someone with insulin resistance, the effects can be subclinical over much of their lifespan, but eventually give rise to clinical manifestations such as prediabetes, dyslipidaemia, hypertension, metabolic syndrome, and hepatic steatosis, contributing to the development of type 2 diabetes, cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease (MASLD).”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.4-6"></a>

### Mechanisms of organ dysfunction

> “Obesity can directly cause organ dysfunction via several pathophysiological mechanisms, including the physical effect of increased adipose tissue mass, the presence of ectopic fat within tissues and organs, metabolic effects, inflammatory mechanisms, and psychological consequences (figure 3).”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.4-7"></a>

### Visceral adiposity and cardiovascular risk

> “There may be a 2- to 3-fold variation in the amount of VAT at any level of total or subcutaneous adiposity.”
> “Thus, high waist circumference (WC) even in individuals with normal weight may unmask higher CVD risk because WC is an indicator of abdominal body fat, which is associated with cardiometabolic disease and CVD and is predictive of mortality.”

Source: [Powell-Wiley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8493650/)

<a id="topic-2.2.1.4-8"></a>

### Pathophysiological and behavioral phenotypes

> “Consequently, four actionable phenotypes were established: abnormal satiation (measured by calories ingested to experience postprandial fullness), abnormal postprandial satiety (duration of fullness and measured by GE), emotional eating behavior (measured by questionnaires) and abnormal resting energy expenditure (measured by indirect calorimetry).”
> “This obesity-phenotype based classification aims to match a treatment to the underlying pathophysiological abnormality seen in patients with obesity.”

Source: [Busebee et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10843116/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
